Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 6:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 897 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Antiretrovirals Clear all
Completed Not applicable Interventional Results available

Texting to Improve Adherence in HIV+ With Bipolar Disorder

NCT02090634
View directory record Official record
Conditions
HIV Disease, Bipolar Disorder
Interventions
Psychoeducation, individualized Texting for Adherence Building (iTAB)
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 27, 2021 · Synced Oct 8, 2026, 6:37 PM EDT
Completed Not applicable Interventional

Immune Activation and Drug Absorption in HIV-Infected Patients

NCT01845298
View directory record Official record
Conditions
HIV Infection
Interventions
Rifampicin 600 mg
Drug
Lead sponsor
Drexel University
Other
Eligibility
21 Years to 45 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 8, 2026, 6:37 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV

NCT02016924
View directory record Official record
Conditions
Acquired Immune Deficiency Syndrome (AIDS), HIV Infections
Interventions
ATV, DRV, Cobicistat, BR, F/TAF, LPV/r, Third Unboosted Drug, Cobicistat TOS, F/TAF TOS
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
4 Weeks to 17 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
7
States / cities
Long Beach, California • Los Angeles, California • Aurora, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 8, 2026, 6:37 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Safety and Antiretroviral Activity of 3BNC117

NCT02588586
View directory record Official record
Conditions
HIV-1 Infection
Interventions
3BNC117, Antiretroviral Treatment Interruption
Drug · Other
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 16, 2021 · Synced Oct 8, 2026, 6:37 PM EDT
Completed Phase 4 Interventional

Contribution of Dolutegravir to Obesity and Cardiovascular Disease

NCT04340388
View directory record Official record
Conditions
HIV-1-infection, Antiviral Drug Adverse Reaction, Vascular Diseases, Cardiovascular Abnormalities, Abnormality of Adipose Tissue, Body Weight Changes, Body Fat Disorder, HIV-Associated Lipodystrophy Syndrome
Interventions
Dolutegravir 50 MG, Antiretroviral/Anti HIV
Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years to 100 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 8, 2026, 6:37 PM EDT
Completed Not applicable Interventional

Antiretroviral Therapy Selection: Comparing HIV Clinical Guidelines With HIV-ASSIST, an Online Decision-support Tool

NCT04080765
View directory record Official record
Conditions
Hiv
Interventions
HIV-ASSIST, DHHS guidelines
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
Not listed
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 12, 2020 · Synced Oct 8, 2026, 6:37 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Relative Mitochondrial Toxicity of Tenofovir Alafenamide (TAF) vs. Tenofovir Disoproxil Fumarate (TDF)

NCT03251144
View directory record Official record
Conditions
HIV/AIDS, Antiviral Toxicity, Antiviral Drug Adverse Reaction, Mitochondrial Alteration
Interventions
Switch to E/C/FTC/TAF daily
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 80 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Oct 8, 2026, 6:37 PM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Getting to Zero Among HHI MSM in the American South

NCT05075967
View directory record Official record
Conditions
HIV Infections
Interventions
Health Access Coalitions, Social Media, Peer Support, Promoting Human Autonomy Support & Empathy (PHASE)
Behavioral
Lead sponsor
HIV Prevention Trials Network
Network
Eligibility
15 Years and older · Male only
Enrollment
2,700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 8, 2026, 6:37 PM EDT
Completed No phase listed Observational

Stopping and Restarting Anti-HIV Drugs in Children and Adolescents With Low Blood Levels of HIV

NCT00016783
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 21 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2006
U.S. locations
16
States / cities
Los Angeles, California • Denver, Colorado • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2013 · Synced Oct 8, 2026, 6:37 PM EDT
Completed Phase 2 Interventional

A Study of an Adherence Plan to Help HIV-Positive Patients Take Their First Anti-HIV Medications Correctly

NCT00001122
View directory record Official record
Conditions
HIV Infections
Interventions
Nelfinavir mesylate, Efavirenz, Stavudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
San Diego, California • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 2, 2011 · Synced Oct 8, 2026, 6:37 PM EDT
Terminated Phase 4 Interventional Results available

Pilot Study of Bydureon to Treat Diabetes in HIV-infected Adults

NCT01791465
View directory record Official record
Conditions
Human Immunodeficiency Virus Infection, Diabetes Mellitus
Interventions
extended-release exenatide
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 99 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 10, 2017 · Synced Oct 8, 2026, 6:37 PM EDT
Completed Phase 3 Interventional Results available

Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults

NCT01967940
View directory record Official record
Conditions
HIV, HIV Infections, Acquired Immunodeficiency Syndrome
Interventions
TAF, Placebo, E/C/F/TAF, Current failing ARV regimen, ATV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
5
States / cities
Ft. Pierce, Florida • West Palm Beach, Florida • Wilton Manors, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2018 · Synced Oct 8, 2026, 6:37 PM EDT
Not listed Not applicable Interventional

High Dose Ritonavir/Lopinavir Liquid Formulation in Salvage Therapy for Protease Inhibitor Resistant HIV Disease

NCT00247143
View directory record Official record
Conditions
HIV, AIDS
Interventions
Kaletra (drug)
Drug
Lead sponsor
Lampiris, Harry W., M.D.
Individual
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 20, 2006 · Synced Oct 8, 2026, 6:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pilot Project of Virologic and Immunologic Correlates of GALT Immune Reconstitution Following Raltegravir Therapy

NCT00661960
View directory record Official record
Conditions
HIV Infections, AIDS
Interventions
raltegravir, efavirenz
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 50 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
2
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 8, 2026, 6:37 PM EDT
Completed Phase 4 Interventional Results available

Omega-3 Fatty Acids for High Triglycerides in HIV-infected Patients

NCT00346697
View directory record Official record
Conditions
HIV Infections, AIDS, Dyslipidemia, Hypertriglyceridemia
Interventions
Omega-3 fatty acid administration, Placebo
Drug
Lead sponsor
Brown, Todd, M.D., Ph.D.
Individual
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
3
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 5, 2014 · Synced Oct 8, 2026, 6:37 PM EDT
Completed Not applicable Interventional

Vitamin D Reabsorption in Adolescents and Young Adults With HIV Infection

NCT00490412
View directory record Official record
Conditions
HIV Infections
Interventions
Vitamin D supplement, Placebo
Dietary Supplement · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 24 Years
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
14
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Oct 8, 2026, 6:37 PM EDT
Terminated Phase 3 Interventional Results available

Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral-Naive Patients Infected With CCR5 Tropic HIV 1

NCT01345630
View directory record Official record
Conditions
HIV-1
Interventions
Maraviroc, Emtricitabine/tenofovir, darunavir/ritonavir 800/100 mg, placebo for emtricitabine/tenofovir, placebo for maraviroc
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
813 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
84
States / cities
Birmingham, Alabama • Hobson City, Alabama • Hayward, California + 45 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2016 · Synced Oct 8, 2026, 6:37 PM EDT
Completed Phase 3 Interventional Results available

Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir

NCT00708162
View directory record Official record
Conditions
HIV Infection
Interventions
Elvitegravir, Raltegravir, EVG placebo, RAL placebo, Background regimen
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
724 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
94
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 59 more
Source: ClinicalTrials.gov public record
Updated May 30, 2016 · Synced Oct 8, 2026, 6:37 PM EDT
Completed Phase 2 Interventional Results available

Proof of Concept Treatment Study of Orally Administered VH4004280 or VH4011499 in HIV-1 Infected Adults

NCT06039579
View directory record Official record
Conditions
HIV Infections
Interventions
VH4004280, VH4011499, VH4004280 Matching Placebo, VH4011499 Matching Placebo, Antiretroviral therapy
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
3
States / cities
Bakersfield, California • DeLand, Florida • Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Oct 8, 2026, 6:37 PM EDT
Completed Phase 1 Interventional

A Study of Anti-HIV Monoclonal Antibody KD-247

NCT00917813
View directory record Official record
Conditions
HIV Infections
Interventions
KD-247, Physiological saline
Drug
Lead sponsor
The Chemo-Sero-Therapeutic Research Institute
Industry
Eligibility
18 Years to 64 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
15
States / cities
Beverly Hills, California • Burbank, California • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2012 · Synced Oct 8, 2026, 6:37 PM EDT
Completed Phase 2 Interventional

Effectiveness of and Immune Response to HIV Vaccination Followed by Treatment Interruption in HIV Infected Patients

NCT00080106
View directory record Official record
Conditions
HIV Infections
Interventions
MRK Ad5 HIV-1 gag vaccine, Vaccine placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
27
States / cities
Los Angeles, California • Palo Alto, California • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 8, 2026, 6:37 PM EDT
Completed No phase listed Observational

IMPAACT P1058A: Pharmacokinetic Effects of New Antiretroviral Drugs on Children, Adolescents and Young Adults

NCT00977756
View directory record Official record
Conditions
HIV Infections
Interventions
Raltegravir (RAL), Atazanavir (ATV), Ritonavir (RTV), Tenofovir (TDF), Etravirine (ETV), Darunavir (DRV), Maraviroc (MVC), Lopinavir/ritonavir (LPV/r)
Drug
Lead sponsor
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Network
Eligibility
6 Years to 21 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2014
U.S. locations
33
States / cities
Birmingham, Alabama • Long Beach, California • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2015 · Synced Oct 8, 2026, 6:37 PM EDT
Not listed Phase 4 Interventional

Effectiveness and Safety of Epivir/Ziagen/Zerit (3TC/ABC/d4T) Versus Epivir/Ziagen/Sustiva (3TC/ABC/EFV) Versus Epivir/Ziagen/Agenerase/Norvir (3TC/ABC/APV/RTV) in HIV Patients Who Have Never Received Treatment

NCT00005017
View directory record Official record
Conditions
HIV Infections
Interventions
Ritonavir, Abacavir sulfate, Amprenavir, Efavirenz, Lamivudine, Stavudine
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 8, 2026, 6:37 PM EDT
Completed No phase listed Observational

A Study to Evaluate the Effect of Anti-HIV Therapy on Lean Tissue (Muscle) in HIV-Positive Patients

NCT00000890
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
20
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 8, 2026, 6:37 PM EDT